This presentations gives a critical overview of the Drug-coated balloons in the BTK-area. Where do we stand and what are the open questions. Review of all available studies and the literature.
6-month results of the Legflow DCB in real-world TASC C&D femoropopliteal lesions, first presented at LINC 2019.
Investigating the iVolution 3rd generation nitinol stent in TASC A&B femoropopliteal lesions : 24-month outcomes in the EVOLUTION study, first presented at LINC 2019.
ZILVER PTX treatment versus bypass surgery for the treatment of TASC C&D fempop lesions.
Final 12-month results of the ZILVERPASS study, first presented at LINC 2019.
This presentations gives an overview on DCB treatment in the BTK area.
What is the current status?
This presentation was presented by Dr. Marc Bosiers at the LINC 2017 Congress.
Preliminary 12-month results on 180 out of 220 patients & preliminary 24-month results on 110 out of 220 patients suggest at least a non-inferiority of Zilver PTX stenting versus prosthetic Above-The-Knee bypass surgery, with similar patency results and less complications.
This presentation was presented by Dr. Marc Bosiers at the LINC 2018, Leipzig conference.
This presentation gives a brief overview on the literature of Drug-Coated Balloons for femoropopliteal arterial disease. What is already proven, and what are the open questions & limitations.
This presentation gives you a brief overview of how we treat femoropopliteal disease. Which type of treatment is best for which type of SFA lesion?
12-month results of the PREVENT study, investigating the Promus Element Plus stent system from Boston Scientific in Below-The-Knee arteries.
70 Critical Limb Ischemia patients were enrolled in 5 different sites, divided over Belgium and Germany.
With 12-month Primary Patency rates of 86.2% & freedom of TLR-rates of 93.0%, there is definitely some evidence for Drug-Eluting-Stents in the CLI-BTK area.